Dhaval K. Shah PhD

Dhaval Shah

Dhaval K. Shah

Contact Information
455 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-4819

Education and Training:

  • PhD, University at Buffalo School of Pharmacy and Pharmaceutical Sciences (2010)
  • MS, National Institute of Pharmaceutical Education and Reserach (2003)
  • BPharm, Gujarat University (2002)


  • Principle Scientist, Translational Research, PK/PD Modeling and Simulation, Pfizer Inc. (2013)
  • Senior Scientist, Translational Research, PK/PD Modeling and Simulation, Pfizer Inc. (2010–2013)

Awards and Honors:

  • UB Exceptional Scholar: 2016 Young Investigator Award (2016)
  • Outstanding Manuscript in Modeling and Simulation Award - 2014 AAPS annual meeting (2014)
  • Individual Performance Awards (2013)
  • 2010 AAPS Graduate Student Symposium Award in PPDM and CPTR (2010)
  • Who’s Who Among Students in American Universities and Colleges (2009)
  • Graduate Scholar Award (2009)
  • AAPS Outstanding Manuscript in Modeling and Simulation Award (2009)
  • First Prize outstanding podium presentation (2009)
  • Best poster and presentation award (2009)
  • Cover page of Journal of PKPD

Grants and Sponsored Research:

  • May 2015–March 2020
    Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics
    Role: Principal Investigator

Journal Articles:

See all (13 more)

Professional Memberships:

  • PK/PD of Novel Biological Construct; Advisory board member (2013–present)
  • Bioanalytical Method & Modeling Integration Summit; Advisory board member (2013–present)
  • The 3rd Pharmacokinetics & Pharmacodynamics; Advisory board member (2012–present)
  • Global PK/PD Network at Pfizer Inc; • Chair (2011–present)
  • The Dean’s Student Ambassador (2008–2010)
  • UB-Pharmaceutics Graduate Student Association; President & Vice President (2007–2008)
  • American Association of Pharmaceutical Scientists; Member (2004–present)


  • "Development of Translational PK Model for Characterizing and Predicting Protein Therapeutics Disposition in Brain" The National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous System Disorders. (2017)
  • "Quantitative Characterization of the Bystander Effect of ADCs." 7th World ADC Summit (2017)
  • "Bench-to-bedside translation of ADCs using PKPD M&S" World Conference on Pharmacometrics (WCOP) (2016)
  • "Model-based Drug Development of Protein Therapeutics" 11th International International Society for the Study of Xenobiotics (ISSX) Meeting (2016)
  • "Platform PBPK Model for Biologics and Its Evolution Towards Pediatric Population" Gordon Research Conference on Drug Metabolism (2015)
  • "Model Based Development of Antibody Drug Conjugates" Clinical & Pharmaceutical Solutions through Analysis Conference 2014 (2014)
  • "Quantitative PKPD Approaches to Guide the Discovery and Development of ADCs" , Green Cross Pharmaceuticals (2014)
  • "Preclinical to Clinical Translation of Antibody Drug Conjugate (ADC) Efficacy using PK/PD Modeling and Simulation" 2013 AAPS Webinar Series, CPTR (2013)
  • "Development and Validation of a Mechanism Based PK/PD Model for Preclinical to Clinical Translation of ADC Efficacy" PK/PD of Antibody-Derived Molecules: Improving Pre-Clinical Results for Clinical Success, PEGS Inaugural (2013)
  • "Development and Validation of the multi-scaled mechanistic PK/PD model for ADCs" PK/PD of Novel Constructs Conference, Cambridge Healthtech Institute (2013)
  • "Employing PK/PD modeling and simulation to guide ADC development" 2013 World ADC Summit (2013)
  • "Evolving PBPK Modeling to Predict the PK and Appropriate Doses of Biotherapeutics for Pediatric Patients" 2013 AAPS NBC Meeting (2013)
  • "Novel Applications of PBPK Models" PK/PD summit (2013)
  • "Overcoming PK/PD barriers to link drug levels with the biological effects in a tumor" 2013 Tumor Model Conference (2013)
  • "A platform PBPK model to characterize the plasma and tissue disposition of mAbs" The 2012 Rozman Symposium, The Delaware Valley DRUG METABOLISM DISCUSSION GROUP (2012)
  • "Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale Mechanistic PK/PD Model: A Case Study with SGN-35" 2012 World-Wide Webinars: Impact of Modeling and Simulation in Drug Development., ROSA‘s (2012)
  • "Preclinical-to-clinical translation of ADC efficacy using the multi-scaled mechanistic PK/PD model" 3rd Pharmacokinetics & Pharmacodynamics Conference, GTC (2012)
  • "Using Mechanistic Preclinical PK/PD Studies to Inform Dose, Dose Regimen Selection and Beyond: Can we make Preclinical Models more Predictive?." World ADC Summit (2012)
  • "Mechanistic Modeling for Rational Selection of Clinical Doses for Biologics" , AAPS (2011)
  • "Treating ovarian cancer using combination of anti-angiogenic therapy and intraperitoneal chemotherapy" , AAPS (2010)
  • "Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy" , University at Buffalo, Pharmaceutical Sciences (2009)
  • "A Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy" PGSRM (2009)
  • "Application of anti-angiogenic therapy to improve drug penetration in solid tumors, following regional chemotherapy" UB/Pfizer monoclonal antibody videoconference (2007)
  • "The role of dehydration and transepidermal water loss in skin barriers function" (2003)
See all (14 more)

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

455 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-4819